32 completed, 19 unknown, 10 recruiting, 5 terminated. 75 Phase 1, 33 Phase 2.
Follow Alopecia: new trials by email Literature Review of Alopecia trials Research Report on Alopecia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| XVIE to Treat Androgenetic Alopecia (AGA) Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution - Androgenetic Alopecia | Phase 1 / Phase 2 | Not yet recruiting | Restore Biologics Holdings, Inc. dba Xtressé | 30 | 2026-12-01 | 2026-08-12 |
| A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata VC005 tablets - Alopecia Areata | Phase 1 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 24 | 2026-09-22 | 2026-10-20 |
| Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration placebo, Baricitinib tablets, IBI3013 - Healthy, Active Non-segmental Vitiligo | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 160 | 2026-04-18 | 2026-04-28 |
| Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia AD-303A, AD-3031 - Androgenetic Alopecia | Phase 1 / Phase 2 | Not yet recruiting | Moogene Medi Co., Ltd | 30 | 2026-04-01 | 2026-03-24 |
| Study of EPI-001 in Patients With Androgenetic Alopecia EPI-001, Placebo - Androgenetic Alopecia | Phase 1 / Phase 2 | Recruiting | Epibiotech | 42 | 2026-01-12 | 2026-06-01 |
| Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients Secretome, Platelet-Rich Plasma (PRP) Injections - Androgenetic Alopecia | Phase 1 / Phase 2 | Recruiting | PT. Prodia Stem Cell Indonesia | 40 | 2026-01-09 | 2026-02-24 |
| A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia OLX72021, Placebo - Androgenetic Alopecia (AGA) | Phase 1 / Phase 2 | Recruiting | Olix Pharmaceuticals, Inc. | 158 | 2025-12-04 | 2026-10-13 |
| Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia SAD IV Dose 1 - 150mg ABS201 IV Single Dose, Placebo IV, ABS-201 SC Multiple Doses - Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female | Phase 1 / Phase 2 | Recruiting | Absci Pty Ltd. | 227 | 2025-12-03 | 2026-10-28 |
| A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. FB102, Placebo - Alopecia Areata | Phase 1 | Recruiting | Forte Biosciences, Inc. | 32 | 2025-10-23 | 2025-11-20 |
| A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes Human umbilical cord mesenchymal stem cell exosomes, Minoxidil 5% Topical Solution - Androgenic Alopecia | Phase 1 / Phase 2 | Recruiting | Shenzhen People's Hospital | 59 | 2025-09-20 | 2025-12-02 |
| Evaluation of Exosomes Injection in Treatment of Male Androgenetic Alopecia: Clinical and Immunohistochemical Study Plasma derived exosomes - Androgenetic Alopecia | Phase 1 / Phase 2 | Not yet recruiting | Ain Shams University | 15 | 2025-08-30 | 2025-08-08 |
| HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata HCW9302, an IL-2 fusion protein - Alopecia Areata(AA) | Phase 1 | Recruiting | HCW Biologics | 30 | 2025-08-16 | 2026-09-15 |
| Autologous Adipose Cells Therapy Autologous Adipose Cells Therapy - Hair Loss/Baldness, Wrinkle Appearance | Phase 1 / Phase 2 | Recruiting | CERM INC. | 40 | 2025-08-01 | 2025-05-31 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration AH-001 or placebo - Androgenetic Alopecia | Phase 1 | Completed | AnHorn Medicines Co. Ltd. | 64 | 2025-03-24 | 2025-12-19 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata ALD-102 Solution, Placebo or Control - Alopecia Areata (AA) | Phase 1 / Phase 2 | Active not recruiting | Aldena Therapeutics | 9 | 2025-03-24 | 2026-11-04 |
| A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) VIS171 - Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA) | Phase 1 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 30 | 2025-03-17 | 2026-07-22 |
| The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. Mesenchymal Stem Cells, 0.9 % saline - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 70 | 2024-12-25 | 2025-01-08 |
| A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo DR-01 - Alopecia Areata, Vitiligo | Phase 1 | Active not recruiting | Dren Bio | 81 | 2024-10-30 | 2026-07-08 |
| Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia 5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling - Androgenetic Alopecia | Phase 1 | Unknown | Levit Dermatology | 100 | 2024-07-01 | 2024-07-16 |
| Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia CG2001, Placebo foam - Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA) | Phase 1 | Completed | Beijing Dayspring Pharmaceutical Technology Co., Ltd | 44 | 2024-03-19 | 2025-06-26 |
Showing 20 of 75. Sign in to see all of them.
Alopecia Areata (21) · Skin Diseases (3) · Acne Vulgaris (2) · Hair Diseases (2) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Dermatitis, Atopic (1) · Head and Neck Neoplasms (1) · Hirsutism (1) · Hypertrichosis (1) · Immune System Diseases (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Hypotrichosis (75) · Skin and Connective Tissue Diseases (75) · Hair Diseases (73) · Skin Diseases (72) · Pathological Conditions, Anatomical (57) · Pathological Conditions, Signs and Symptoms (57) · Neoplasms (3) · Acneiform Eruptions (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Neoplasms by Site (2)
Minoxidil (7) · Finasteride (4) · Bimatoprost (3) · Sodium Chloride (3) · Solutions (3) · Latanoprost (2) · Tablets (2) · Vitamin D (2) · baricitinib (2) · AH 001 (1) · Betamethasone (1) · Betamethasone Valerate (1) · Calcitriol (1) · Cyclophosphamide (1) · Digestion (1)
Suzhou Kintor Pharmaceutical Inc, (4) · Allergan (3) · Chong Kun Dang Pharmaceutical (2) · Dong-A ST Co., Ltd. (2) · Histogen (2) · Kasiak Research Pvt. Ltd. (2) · Siriraj Hospital (2) · Technoderma Medicines Inc. (2) · Absci Pty Ltd. (1) · Addpharma Inc. (1) · Ahmed Hassan Nouh MD (1) · Aileron Therapeutics, Inc. (1) · Ain Shams University (1) · Aldena Therapeutics (1) · Alexandria University (1)
United States (27) · Australia (9) · China (7) · Egypt (7) · South Korea (7) · Canada (3) · New Zealand (3) · Bulgaria (2) · India (2) · Pakistan (2) · Thailand (2) · Bosnia and Herzegovina (1) · France (1) · Georgia (1) · Germany (1)
Daniel Piacquadio, M.D. (2) · Rajendarsingh Rajput, Dr. (2) · Sandeep Sattur, Dr. (2) · Alison Bruce, M.B. Ch.B (1) · Betsy Hughes-Formella, PhD (1) · Danielle McGeeney (1) · David J Wyatt, MD (1) · Dr. Abdollah M. Malekzadeh, MD, MD (1) · Dr. Arun Kumar, PhD (1) · Eisa Mohammed Hegazy, professor (1) · Essam A Nada, MD (1) · Eyal K Levit, M.D. (1) · Hoon Kang, M.D, Ph.D (1)
PMID 18645136, PMID 19620039, PMID 20115946, PMID 21199096, PMID 21712909, PMID 21899919, PMID 24872229, PMID 25601618, PMID 25765294, PMID 25896390, PMID 27536459, PMID 30302901, PMID 31245963, PMID 31321800, PMID 31574029, PMID 32478930, PMID 38833144, PMID 39924925